Drug delivery to the brain via the blood-brain barrier: A review of the literature and some recent patent disclosures

Therapeutic Delivery

Volumn 2, Issue 3, 2011, Pages 311-327

  Tucker, Ian G ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APROTININ; CHOLINERGIC RECEPTOR; DAUNORUBICIN; DIPHTHERIA TOXIN; DNA; DOXORUBICIN; ETOPOSIDE; GLUTATHIONE; HUMAN SERUM ALBUMIN; IMMUNOLIPOSOME; INSULIN ANTIBODY; INSULIN RECEPTOR; LACTOFERRIN; LEPTIN; LEPTIN RECEPTOR; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 ARGININE]; LIPOSOME; LOPERAMIDE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; NANOPARTICLE; PACLITAXEL; POLYSORBATE 80; PROTEIN P97; SMALL INTERFERING RNA; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNINDEXED DRUG; ZIDOVUDINE;

AMINO ACID SEQUENCE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; BRAIN METASTASIS; BRAIN TUMOR; CELL PERMEABILIZATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; GENE DELIVERY SYSTEM; HUMAN; NONHUMAN; PHARMACEUTICS; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR BINDING; REVIEW; TIGHT JUNCTION; TRANSCYTOSIS;

EID: 79952679752     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.3     Document Type: Review

References (114)

1. Pardridge WM. Why is the global CNS pharmaceutical market so under-penetrated? Drug Discov. Today 7(1), 5-7 (2002). (Pubitemid 34093938)
2. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2(1), 3-14 (2005). (Pubitemid 40128022)
3. Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery NeuroRx 2(4), 554-571 (2005). (Pubitemid 41393265)
4. Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fuid/blood-brain barrier for treatment of central nervous system infections. Clin. Microbiol. Rev. 23(4), 858-883 (2010).
5. Spector R, Johanson CE. Vectorial ligand transport through mammalian choroid plexus. Pharm. Res. 27(10), 2054-2062 (2010).
6. Jogani V, Jinturkar K, Vyas TK, Misra A. Recent patents review on intranasal administration for CNS drug delivery Recent Pat. Drug Deliv. Formul. 2(1), 25-40 (2008). (Pubitemid 351546432)
7. Dhuria SV, Hanson LR, Frey Ii WH. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci. 99(4), 1654-1673).
8. Salvatore MF, Ai Y, Fischer B et al. Point source concentration of GDNF may explain failure of Phase II clinical trial. Exp. Neurol. 202(2), 497-505 (2006). (Pubitemid 44692690)
9. Jones AR, Shusta EV. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm. Res. 24(9), 1759-1771 (2007). (Pubitemid 47206625)
10. Potschka H. Targeting the brain-surmounting or bypassing the blood-brain barrier. Handb. Exp. Pharmacol. 197, 411-431 (2010).
11. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol. Dis. 37(1), 48-57 (2010).
12. Wang BY, Xia AX, Chen PP, Ni L, Liu FH, Li FZ. Blood-brain barrier transport of drug-loaded nanoparticle: research advances. J. Int. Pharm. Res. 37(1), 40-42 (2010).
13. Ligade PC, Jadhav KR, Kadam VJ. Brain drug-delivery system: an overview. Curr. Drug Ther. 5(2), 105-110 (2010).
14. Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol. Dis. 37(1), 13-25 (2010).
15. Pries AR, Kuebler WM. Normal endothelium. Handb. Exp. Pharmacol. 176(Part 1), 1-40 (2006).
16. Campbell M, Kiang AS, Kenna PF et al. RNAi-mediated reversible opening of the blood-brain barrier. J. Gene Med. 10(8), 930-947 (2008).
17. Campbell M, Ozaki E, Humphries P. Systemic delivery of therapeutics to neuronal tissues: a barrier modulation approach. Expert Opin. Drug Deliv. 7(7), 859-869 (2010).
18. Wolburg H, Noell S, Mack A, Wolburg-Buchholz K, Fallier-Becker P. Brain endothelial cells and the glio-vascular complex. Cell Tissue Res. 335(1), 75-96 (2009).
19. Fischer H, Gottschlich R, Seelig A. Blood-brain barrier permeation: molecular parameters governing passive diffusion. J. Membr. Biol. 165(3), 201-211 (1998). (Pubitemid 28465226)
20. Seelig A, Gerebtzoff G. Enhancement of drug absorption by noncharged detergents through membrane and P-glycoprotein binding. Expert Opin. Drug Metabol. Toxicol. 2(5), 733-752 (2006). (Pubitemid 46118318)
21. Dallas S, Miller DS, Bendayan R. Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol. Rev. 58(2), 140-161 (2006).
22. Miller DS. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol. Sci. 31, 246-254 (2010).
23. Tsuji A. Small-molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx 2(1), 54-62 (2005). (Pubitemid 40128026)
24. Ricci M, Blasi P, Giovagnoli S, Rossi C. Delivering drugs to the central nervous system: a medicinal chemistry or a pharmaceutical technology issue? Curr. Med. Chem. 13(15), 1757-1775 (2006). (Pubitemid 43871754)
25. Giacomini KM, Huang SM, Tweedie DJ et al. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9(3), 215-236 (2010).
26. Pardridge WM. Biopharmaceutical drug targeting to the brain. J. Drug Target. 18(3), 11 (2010).
27. Mahar Doan KM, Humphreys JE, Webster LO et al. Passive permeability and P-glycoprotein-mediated effux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 303(3), 1029-1037 (2002). (Pubitemid 35424386)
28. Thomas FC, Taskar K, Rudraraju V et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm. Res. 26(11), 2486-2494 (2009).
29. Schnyder A, Huwyler J. Drug transport to brain with targeted liposomes. NeuroRx 2(1), 99-107 (2005). (Pubitemid 40128030)
30. Pardridge WM, Triguero D, Buciak J, Yang J. Evaluation of cationized rat albumin as a potential blood-brain barrier drug transport vector. J. Pharmacol. Exp. Ther. 255(2), 893-899 (1990).
31. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodefciency virus. Cell 55(6), 1189-1193 (1988). (Pubitemid 19020071)
32. Schmidt N, Mishra A, Lai GH, Wong GCL. Arginine-rich cell-penetrating peptides. FEBS Lett. 584(9), 1806-1813 (2010).
33. Wender PA, Galliher WC, Goun EA, Jones LR, Pillow TH. The design of guanidinium-rich transporters and their internalization mechanisms. Adv. Drug Deliv. Rev. 60(4-5), 452-472 (2008).
34. Lee HJ, Pardridge WM. Pharmacokinetics and delivery of tat and t1-protein conjugates to tissues in vivo. Bioconjug. Chem. 12(6), 995-999 (2001). (Pubitemid 33136870)
35. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc. Natl Acad. Sci. USA 101(51), 17867-17872 (2004). (Pubitemid 40051978)
36. Pham W, Zhao BQ, Lo EH, Medarova Z, Rosen B, Moore A. Crossing the blood-brain barrier: a potential application of myristoylated polyarginine for in vivo neuroimaging. NeuroImage 28(1), 287-292 (2005). (Pubitemid 41393908)
37. Dehouck B, Fenart L, Dehouck MP, Pierce A, Torpier G, Cecchelli R. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J. Cell Biol. 138(4), 877-889 (1997). (Pubitemid 27365049)
38. Fillebeen C, Descamps L, Dehouck MP et al. Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. J. Biol. Chem. 274(11), 7011-7017 (1999).
39. Demeule M, Poirier J, Jodoin J et al. High transcytosis of melanotransferrin (P97) across the blood-brain barrier. J. Neurochem. 83(4), 924-933 (2002). (Pubitemid 35316043)
40. Demeule M, Regina A, Che C et al. Identifcation and design of peptides as a new drug delivery system for the brain. J. Pharmacol. Exp. Ther. 324(3), 1064-1072 (2008). (Pubitemid 351397849)
41. Abulrob A, Zhang J, Tanha J, MacKenzie R, Stanimirovic D. Single domain antibodies as blood-brain barrier delivery vectors. Int. Congr. Ser. 1277, 212-223 (2005). (Pubitemid 43693326)
42. Muruganandam A, Tanha J, Narang S, Stanimirovic D. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J. 16(2), 240-242 (2002).
43. Tanha J, Muruganandam A, Stanimirovic D. Phage display technology for identifying specifc antigens on brain endothelial cells. Methods Mol. Med. 89, 435-449 (2003).
44. Abulrob A, Sprong H, Van Bergen En Henegouwen P, Stanimirovic D. The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J. Neurochem. 95(4), 1201-1214 (2005). (Pubitemid 41713502)
45. Rip J, Schenk GJ, De Boer AG. Differential receptor-mediated drug targeting to the diseased brain. Expert Opin. Drug Deliv. 6(3), 227-237 (2009).
46. Shi N, Zhang Y, Zhu C, Boado RJ, Pardridge WM. Brain-specifc expression of an exogenous gene after i.v. administration. Proc. Natl Acad. Sci. USA 98(22), 12754-12759 (2001). (Pubitemid 33026054)
47. Mishra V, Mahor S, Rawat A et al. Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J. Drug Target. 14(1), 45-53 (2006).
48. Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin-and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur. J. Pharm. Biopharm. 71(2), 251-256 (2009).
49. Pardridge WM, Buciak JL, Friden PM. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J. Pharmacol. Exp. Ther. 259(1), 66-70 (1991).
50. Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl Acad. Sci. USA 93, 14164-14169 (1996). (Pubitemid 26424263)
51. Gosk S, Vermehren C, Storm G, Moos T. Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J. Cereb. Blood Flow Metab. 24(11), 1193-1204 (2004). (Pubitemid 39482480)
52. Zhang Y, Pardridge WM. Near complete rescue of experimental Parkinson's disease with intravenous, nonviral GDNF gene therapy. Pharm. Res. 26(5), 1059-1063 (2009).
53. Boado RJ, Zhou QH, Lu JZ, Hui EKW, Pardridge WM. Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor. Mol. Pharm. 7(1), 237-244 (2010).
54. Pardridge WM, Kang YS, Buciak JL, Yang J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm. Res. 12(6), 807-816 (1995).
55. Boado RJ, Zhang Y, Pardridge WM. Humanization of antihuman insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol. Bioeng. 96(2), 381-391 (2007). (Pubitemid 46232272)
56. Boado RJ, Hui EKW, Lu JZ, Zhou QH, Pardridge WM. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. J. Biotechnol. 146(1-2), 84-91 (2010).
57. Davis B, Morris T. Physiological parameters in laboratory animals and humans. Pharm. Res. 10(7), 1093-1095 (1993). (Pubitemid 23211439)
58. Boado RJ, Pardridge WM. Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey. Drug Metab. Dispos. 37(12), 2299-2304 (2009).
59. Pardridge WM, Boado RJ. Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery. Pharm. Res. 26(10), 2227-2236 (2009).
60. Boado RJ, Zhang Y, Xia CF, Pardridge WM. Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and Ab fibril disaggregation. Bioconjug. Chem. 18(2), 447-455 (2007) (Pubitemid 46493516)
61. Pardridge WM. shRNA and siRNA delivery to the brain. Adv. Drug Deliv. Rev. 59(2-3), 141-152 (2007). (Pubitemid 46773051)
62. Pardridge WM. Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy. NeuroRx 2(1), 129-138 (2005). (Pubitemid 40128033)
63. Ulbrich K, Knobloch T, Kreuter J. Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB). J. Drug Target. 19(2), 125-132 (2011).
64. Golden PL, Maccagnan TJ, Pardridge WM. Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels. J. Clin. Invest. 99(1), 14-18 (1997). (Pubitemid 27058288)
65. Couce ME, Green D, Brunetto A, Lloyd RV, Burguera B. Limited brain access for leptin in obesity. Pituitary 4(1-2), 101-110 (2001). (Pubitemid 34081086)
66. Kurrimbux D, Gaffen Z, Farrell CL, Martin D, Thomas SA. The involvement of the blood-brain and the blood-cerebrospinal fluid barriers in the distribution of leptin into and out of the rat brain. Neuroscience 123(2), 527-536 (2004). (Pubitemid 38032928)
67. Barrett GL, Trieu J, Naim T. The identification of leptin-derived peptides that are taken up by the brain. Regul. Pept. 155(1-3), 55-61 (2009).
68. Liu Y, Li J, Shao K et al. A leptin derived 30-amino-acid peptide modified pegylated poly-l-lysine dendrigraft for brain targeted gene delivery. Biomaterials 31(19), 5246-5257 (2010).
69. Banks WA, Clever CM, Farrell CL. Partial saturation and regional variation in the blood-to-brain transport of leptin in normal weight mice. Am. J. Physiol. Endocrinol. Metab. 278(6), E1158-E1165 (2000). (Pubitemid 30439155)
70. Nykjaer A, Willnow TE. The low-density lipoprotein receptor gene family: a cellular Swiss army knife? Trends Cell Biol. 12(6), 273-280 (2002). (Pubitemid 34634176)
71. May P, Woldt E, Matz RL, Boucher P. The LDL receptor-related protein (LRP) family: an old family of proteins with new physiological functions. Ann. Med. 39(3), 219-228 (2007). (Pubitemid 46676481)
72. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J. Clin. Invest. 112(10), 1533-1540 (2003). (Pubitemid 38056279)
73. Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol. Rev. 88(3), 887-918 (2008).
74. Gosselet F, Candela P, Sevin E, Berezowski V, Cecchelli R, Fenart L. Transcriptional profiles of receptors and transporters involved in brain cholesterol homeostasis at the blood-brain barrier: use of an in vitro model. Brain Res. 1249(C), 34-42 (2009).
75. Candela P, Gosselet F, Miller F et al. Physiological pathway for low-density lipoproteins across the blood-brain barrier: transcytosis through brain capillary endothelial cells in vitro. Endothelium 15(5-6), 254-264 (2008).
76. Tucker IG, Florence AT. Interactions of ionic and nonionic surfactants with plasma low density lipoprotein. J. Pharm. Pharmacol. 35(11), 705-711 (1983). (Pubitemid 14234171)
77. Lacko AG, Nair M, Prokai L, McConarthy WJ. Prospects and challenges of the development of lipoprotein-based formulations for anticancer drugs. Expert Opin. Drug Deliv. 4(6), 665-675 (2007). (Pubitemid 350193401)
78. Nikanjam M, Blakely EA, Bjornstad KA, Shu X, Budinger TF, Forte TM. Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int. J. Pharm. 328(1), 86-94 (2007). (Pubitemid 44827556)
79. Nikanjam M, Gibbs AR, Hunt CA, Budinger TF, Forte TM. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J. Control. Release 124(3), 163-171 (2007). (Pubitemid 350101886)
80. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 674(1), 171-174 (1995).
81. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 47(1), 65-81 (2001). (Pubitemid 32209233)
82. Kreuter J, Shamenkov D, Petrov V et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target. 10(4), 317-325 (2002). (Pubitemid 34746313)
83. Olivier J-C. Drug transport to brain with targeted nanoparticles. NeuroRx 2, 108-119 (2005). (Pubitemid 40128031)
84. Kim HR, Andrieux K, Gil S et al. Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins on receptor-mediated endocytosis. Biomacromolecules 8(3), 793-799 (2007). (Pubitemid 46488459)
85. Kim HR, Gil S, Andrieux K et al. Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. Cell Mol. Life Sci. 64(3), 356-364 (2007). (Pubitemid 46440206)
86. Gelperina S, Maksimenko O, Khalansky A et al. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: infuence of the formulation parameters. Eur. J. Pharm. Biopharm. 74(2), 157-163 (2010).
87. Zensi A, Begley D, Pontikis C et al. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J. Control. Release 137(1), 78-86 (2009).
88. Zensi A, Begley D, Pontikis C et al. Human serum albumin nanoparticles modifed with apolipoprotein A-I cross the blood-brain barrier and enter the rodent brain. J. Drug Target. 18(10), 842-848 (2010).
89. Spencer BJ, Verma IM. Targeted delivery of proteins across the blood-brain barrier. Proc. Natl Acad. Sci. USA 104(18), 7594-7599 (2007). (Pubitemid 47185951)
90. Pan W, Kastin AB, Zankel TC, van Kerkhof P, Terasaki T, Bu G. Effcient transfer of receptor-associated protein (RAP) across the blood-brain barrier. J. Cell Sci. 117(21), 5071-5078 (2004). (Pubitemid 39517522)
91. Gabathuler R, Arthur G, Kennard M et al. Development of a potential protein vector (NeuroTrans) to deliver drugs across the blood-brain barrier. Int. Congr. Ser. 1277, 171-184 (2005). (Pubitemid 43693327)
92. Karkan D, Pfeifer C, Vitalis TZ et al. A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier. PLoS ONE 3 (6), e2469 (2008).
93. Huang R, Ke W, Han L et al. Brain-targeting mechanisms of lactoferrin-modifed DNA-loaded nanoparticles. J. Cereb. Blood Flow Metab. 29(12), 1914-1923 (2009).
94. Huang R, Ke W, Han L et al. Lactoferrin-modifed nanoparticles could mediate effcient gene delivery to the brain in vivo. Brain Res. Bull. 81(6), 600-604 (2010).
95. Huang R, Ke W, Liu Y et al. Gene therapy using lactoferrin-modifed nanoparticles in a rotenone-induced chronic Parkinson model. J. Neurol. Sci. 290(1-2), 123-130 (2010).
96. Demeule M, Currie JC, Bertrand Y et al. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain-delivery vector Angiopep-2. J. Neurochem. 106(4), 1534-1544 (2008).
97. Regina A, Demeule M, Che C et al. Anti-tumor activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br. J. Pharmacol. 155(2), 185-197 (2008).
98. Gabathuler R. Development of new peptide vectors for the transport of therapeutic across the blood-brain barrier. Ther. Deliv. 1(4), 571-586 (2010).
99. Che C, Yang G, Thiot C et al. New angiopep-modifed doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration. J. Med. Chem. 53(7), 2814-2824 (2010).
100. Ke W, Shao K, Huang R et al. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modifed polyamidoamine dendrimer. Biomaterials 30(36), 6976-6985 (2009).
101. Kumar P, Wu H, McBride JL et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 448(7149), 39-43 (2007). (Pubitemid 47037001)
102. Lafon M. Rabies virus receptors. J. Neurovirol. 11(1), 82-87 (2005). (Pubitemid 40458377)
103. Wessler I, Kirkpatrick CJ. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br. J. Pharmacol. 154(8), 1558-1571 (2008).
104. Gotti C, Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog. Neurobiol. 74(6), 363-396 (2004). (Pubitemid 40092737)
105. Abbruscato TJ, Lopez SP, Mark KS, Hawkins BT, Davis TP. Nicotine and cotinine modulate cerebral microvascular permeability and protein expression of ZO-1 through nicotinic acetylcholine receptors expressed on brain endothelial cells. J. Pharm. Sci. 91(12), 2525-2538 (2002). (Pubitemid 35379411)
106. Pulford B, Reim N, Bell A et al. Liposome-siRNA-peptide complexes cross the blood-brain barrier and signifcantly decrease PrPC on neuronal cells and PrPRES in infected cell cultures. PLoS ONE 5(6), 1-13 (2010).
107. Liu Y, Huang R, Han L et al. Brain-targeting gene delivery and cellular internalization mechanisms for modifed rabies virus glycoprotein RVG29 nanoparticles. Biomaterials 30(25), 4195-4202 (2009).
108. Wilkins ME, Li X, Smart TG. Tracking cell surface GABAB receptors using an α-bungarotoxin tag. J. Biol. Chem. 283(50), 34745-34752 (2008).
109. Zhang Y, Liu GQ. Sodium and chloride-dependent high and low-affnity uptakes of GABA by brain capillary endothelial cells. Brain Res. 808(1), 1-7 (1998). (Pubitemid 29003193)
110. Chen W, Zhan C, Gu B et al. Targeted brain delivery of itraconazole via RVG29 anchored nanoparticles. J. Drug Target. DOI: 10.3109/1061186X.1062010. 1492523 (2010) (Epub ahead of print).
111. Xiang L, Zhou R, Fu A, Xu X, Huang Y, Hu C. Targeted delivery of large fusion protein into hippocampal neurons by systemic administration. J. Drug Target. DOI: 10.3109/1061186X.1062010.1523788 (2010) (Epub ahead of print).
112. Gaillard PJ, Brink A, de Boer AG. Diphtheria toxin receptor-targeted brain drug delivery Int. Congr. Ser. 1277, 185-198 (2005). (Pubitemid 43693328)
113. Gaillard PJ, de Boer AG. A novel opportunity for targeted drug delivery to the brain. J. Control. Release 116(2), e60-e62 (2006).
114. Anonymous. To-BBB: leverages new platform to target brain tumours, form partnerships. Neurotech Insights. 6(8), 19 (2010).